Omberacetam (Noopept)

Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulation and glutamatergic modulation at doses 1000x lower than piracetam.

• Memory Enhancement
• Learning Acceleration
• Focus and Concentration

Primary administration route, rapid oral bioavailability, convenient dosing, well-studied in clinical trials, peak absorption within 7 minutes

Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission

Research protocols from published literature — not dosing recommendations.

• Semax — Synergistic: Complementary cognitive enhancement through different mechanisms - Semax via ACTH pathways, Omberacetam via glutamatergic/cholinergic modulation
• Selank — Synergistic: Selank provides anxiolytic effects that may complement Omberacetam's cognitive enhancement, potentially reducing nootropic-induced anxiety
• NA-Semax-Amidate — Monitor Combination: Both compounds affect neurotransmitter systems - monitor for overstimulation when combining
• Cerebrolysin — Compatible: Both support neuroplasticity through neurotrophic mechanisms; may have additive neuroprotective effects
• Dihexa — Use Caution: Both are potent cognitive enhancers affecting growth factors - potential for excessive stimulation; start with lower doses if combining
• Choline Sources — Synergistic: Omberacetam increases acetylcholine sensitization; choline supplementation (Alpha-GPC, CDP-Choline) may prevent headaches and enhance effects

Days 1-3: Subtle cognitive clarity and mild focus enhancement; possible initial headache if not using choline. Week 1: Noticeable improvement in memory recall and verbal fluency; adjust dosing as needed. Week 2-3: Enhanced learning capacity and sustained attention; mood stabilization effects may emerge. Week 4-6: Peak cognitive benefits with improved stress resilience and mental stamina. Week 6-8: Sustained effects; consider cycle break to maintain sensitivity. Post-cycle: Gradual return to baseline over 1-2 weeks; some users report lasting improvements.

Start with 10mg once daily to assess individual response before increasing dose. Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches. Avoid evening dosing as cognitive stimulation may interfere with sleep. Do not combine with other strong cholinergic or glutamatergic compounds without caution. Not recommended for pregnant or breastfeeding women due to lack of safety data. Individuals with liver conditions should consult healthcare provider before use.

Start with 10mg once daily to assess individual response before increasing dose. Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches. Avoid evening dosing as cognitive stimulation may interfere with sleep. Do not combine with other strong cholinergic or glutamatergic compounds without caution. Not recommended for pregnant or breastfeeding women due to lack of safety data. Individuals with liver conditions should consult healthcare provider before use.

Omberacetam (Noopept) should be stored at Room temperature, protect from moisture and light.